In the latest trading session, Novo Nordisk (NVO) closed at $78.79 ... It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong ...

Novo Nordisk's hopes of heralding a new era of obesity ... In the meantime, questions remain around CagriSema's tolerability, with fewer than two-thirds of patients progressing to the highest ...

Shares of Novo Nordisk have surged more than 185% in the past five years. During the same time frame, total revenues have jumped 129% on a reported basis, while the net profit margin consistently ...

Software giant SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable company, in the latest ...

CagriSema is one of a growing number of drugs being developed to show that hitting two targets is better than one for achieving weight loss. It’s important for Novo Nordisk, which has several ...

LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... and definitely a lot of fear out here, that seems to me to be a little bit misplaced on the charts.” ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...